Citations

Clear

16280 citation(s) found for "Yu, David".

Tau biology, biomarkers, and therapeutics
Kolb, Hartmuth C. , DeVos, Sarah L. , Edelmayer, Rebecca M. , Elwood, Fiona , Fleisher, Adam , Henley, David , Kreisl, William Charles, Kulic, Luka , Leuzy, Antoine , Parmentier‐Batteur, Sophie, Patru, Maria‐Magdalena, Rabinovici, Gil D. , Reyderman, Larisa, Geyten, Serge Van der , Wildsmith, Kristin R., Carrillo, Marı́a C., Weber, Christopher J., Carrillo, María C. , Rabinovici, Gil D , Frost, Bess , Algeciras‐Schimnich, Alicia , Betthauser, Tobey J. , Horie, Kanta , Hyman, Bradley T. , Palma, Jose-Alberto , Sperling, Reisa Anne , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | October 21, 2025 | Volume: 11 | Issue: 4 | Pages: No page available

10.1002/trc2.70165 | PMID 41126950 Get It

Abstract As Alzheimer's disease (AD) research advances, tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development. The Fall 2024 Alzheimer's Association Research Roundtable convened experts from academia, industry, National Institutes of Health (NIH), and the United States Food and Drug Administration (FDA) to explore current progress and future directions in tau‐centered diagnostics and therapeutics. Discussions addressed the integration of tau biomarkers into the 2024 Revised Diagnostic Criteria for AD, updates to amyloid and tau positron emission tomography (PET) imaging, and modeling of biomarker trajectories. Presenters highlighted tau‐targeting therapeutics including antisense oligonucleotides, monoclonal antibodies, and small molecules, alongside innovations in drug delivery. The interplay between anti‐amyloid and anti‐tau therapies and strategic design of combination trials were key themes. Regulatory insights facilitated discussions on drug approval pathways. The meeting highlighted the rapid evolution of tau research and emphasized opportunities to improve diagnostics, trial design, and treatment strategies in AD. Highlights The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to explore current progress and future directions in tau‐centered diagnostics and therapeutics. Tau has emerged as both a critical biomarker and a promising therapeutic target, central to understanding disease mechanisms, tracking progression, and guiding treatment development. Discussions addressed the integration of tau biomarkers into the 2024 revised diagnostic criteria for AD, updates to amyloid and tau PET imaging, modeling of biomarker trajectories, tau‐targeting therapeutics, and interplay between anti‐amyloid and anti‐tau therapies and strategic design of combination trials.
What Is Clinical Anatomy?—A Consensus Statement From the American Association of Clinical Anatomists
Rajaram‐Gilkes, Mathangi, Chaiyamoon, Arada , Ezra, David , Raoof, Ameed , Rae, Guenevere , Mtui, Estomih P., Detton, Alan J., Anand, Mahindra , Raeburn, Kazzara , Kim, Hee‐Jin , Sekhar, Laligam N., Watanabe, Koichi , D’Antoni, Anthony V. , Loukas, Marios , Spinner, Robert J. , Tubbs, R. Shane, Iwanaga, Joe , Ezra, David , Rae, Guenevere , Kim, Hee-Jin , Watanabe, Koichi , Antoni, Anthony D' , Loukas, Marios , Spinner, Robert J , Adds, Philip , Iwanaga, Joe , Bubb, Kathleen , Rajaram-Gilkes, Mathangi, Noël, Geoffroy P. J. C. , Hur, Mi-Sun , Sekhar, Laligam N. , Tabira, Yoko , Khalil, Mohammed K. , Adds, Philip J.

Mayo Clinic

Clinical Anatomy | October 21, 2025 | Volume: 39 | Issue: 1 | Pages: 72-76

10.1002/ca.70040 | PMID 41117176 Get It

ABSTRACT At the 42nd Annual Meeting of the American Association of Clinical Anatomists (AACA) in Bellevue, Washington, June 2025, two inaugural events—the Clinical Anatomy Fireside Chat (CAFC) and the Clinical Anatomy Symposium: Head and Neck 2025 (CAS)—fostered rich dialogue on the evolving role and operational definition of clinical anatomy. Experts from various clinical and anatomical disciplines explored the meaning of clinical anatomy, highlighting the absence of a universal definition despite its frequent use in education and research. Through these interdisciplinary discussions, a consensus emerged: clinical anatomy is not defined solely by the possession of clinical credentials but by the integration of anatomical knowledge and clinical relevance, achieved most effectively through collaboration. Clinical anatomy education and research require different depths of clinical knowledge depending on the audience and objective, and meaningful collaboration can bridge gaps in expertise. The symposium further illustrated that high‐quality clinical anatomy emerges from mutual respect and reciprocal insight between clinicians and anatomists. This article presents a consensus statement developed by AACA representatives and invited speakers, affirming that collaboration is not only foundational to the practice of clinical anatomy but also fundamental to its definition. These conclusions aim to guide future educational models, research strategies, and interdisciplinary partnerships in the field of clinical anatomy.
Standalone Endovascular Embolization versus Stereotactic Radiosurgery in the Treatment of Arteriovenous Malformations in Eloquent Brain
Musmar, Basel , Abdalrazeq, Hammam , Adeeb, Nimer , Salim, Hamza , Roy, Joanna M. , Aslan, Assala , Tjoumakaris, Stavropoula I., Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Hanalıoğlu, Şahin , Erginoğlu, Ufuk , Sen, Rajeev , Burkhardt, Jan‐Karl , Starke, Robert M. , Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan, Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael, Guthikonda, Bharat , Salim, Hamza , Riina, Howard , Dmytriw, Adam A , Gummadi, Sanjeev , Ataoglu, Cagdas , Essibayi, Muhammed Amir , Keles, Abdullah , Muram, Sandeep , Alwakaa, Omar , Mantziaris, Georgios , Park, Min S , Hanalioglu, Sahin , Erginoglu, Ufuk , Pöppe, Johannes , Griessenauer, Christoph J , Starke, Robert M , Levitt, Michael R , Altschul, David J , Haranhalli, Neil , Zeineddine, Hussein A , Atallah, Elias , Stapleton, Christopher , Koch, Matthew J , Srinivasan, Visish M , Chen, Peng R , Blackburn, Spiros , Bulsara, Ketan , Choudhri, Omar , Pukenas, Bryan , Smith, Edward , Alaraj, Ali , Patel, Aman B , Notarianni, Christina , Jabbour, Pascal , Musmar, Basel , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Sen, Rajeev D., Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Abla, Adib A. , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Pukenas, Bryan , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

Radiology | October 21, 2025 | Volume: 317 | Issue: 1 | Pages: No page available

10.1148/radiol.250329 | PMID 41117652 Get It

Stereotactic radiosurgery was associated with a higher obliteration rate compared with embolization in patients with eloquent brain arteriovenous malformations, whereas there was no evidence of a difference in functional outcomes or complications after adjustment.
Primary Merkel Cell Carcinoma of the Deep Breast Parenchyma
Nielson, Kaitlyn J. , Cook, David , Hieken, Tina J. , Olave, Maria C. , Solanki, Malvika , Guo, Ruifeng , Jiménez, Rafael E. , Cook, David J , Solanki, Malvika H , Hieken, Tina J , Guo, Ruifeng

Mayo Clinic

International Journal of Surgical Pathology | October 21, 2025 | Volume: 34 | Issue: 2 | Pages: 559-563

10.1177/10668969251384887 | PMID 41117418 Get It

Neuroendocrine carcinomas of the breast are a rare subtype of invasive breast carcinomas, and those with morphologic and immunophenotypic features supporting Merkel cell carcinoma (MCC) are even more rare. Accurate diagnosis of these entities is important for clinical decision-making regarding the selection of optimal treatments. We report a patient withMCC in the deep breast parenchyma of a 52-year-old woman, without evidence of a cutaneous component. This tumor exhibited characteristic morphologic and immunophenotypic features of MCC, including sheets of high grade, hyperchromatic tumor cells, with perinuclear dot-like staining of keratin 20. To our knowledge, this is the sixth report of parenchymal breast MCC, and due to its rarity and aggressive course, we reviewed the literature, including prior experience on its diagnosis and management.
International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine
Yuan, Hsiangkuo , Orr, Serena L. , Al‐Karagholi, Mohammad Al‐Mahdi , Ashina, Messoud , Cohen, Fred , Diener, Hans‐Christoph , Marmura, Michael J. , Martinelli, Daniele , Matharu, Manjit , Simmonds, Lucy , Tassorelli, Cristina , Tepper, Stewart J. , Al-Karagholi, Mohammad A M , Marmura, Michael J , Martinelli, Daniele , Matharu, Manjit Singh , Petersen, Anja S , Pozo-Rosich, Patricia , Sacco, Simona , Simmonds, Lucy , Tassorelli, Cristina , Terwindt, Gisela , Wang, Shuu-Jiun , Yeh, Jiunn-Tyng , Silberstein, Stephan D , Diener, Hans-Christoph , Ashina, Messoud , Yuan, Hsiangkuo , Dodick, David W. , Jensen, Rigmor , Pozo‐Rosich, Patricia , Sacco, Simona , Terwindt, Gisela M. , Wang, Shuu‐Jiun , Silberstein, Stephen D.

Mayo Clinic

Cephalalgia | October 21, 2025 | Volume: 45 | Issue: 10 | Pages: No page available

10.1177/03331024251388377 | PMID 41117312 Get It

Objective To develop evidence-based clinical practice guidelines for non-invasive neuromodulation devices in acute and preventive migraine treatment. Methods A systematic review was conducted across six databases from 1946 to April 2025. Randomized controlled trials evaluating Food and Drug Administration-cleared or Conformité Européenne (CE)-marked non-invasive neuromodulation devices were included. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, and recommendations were developed through consensus following GRADE Evidence-to-Decision frameworks. The working group comprised 15 senior members and six junior members. Results From 1536 initial records, 15 studies met the inclusion criteria and were finally used to develop evidence-based recommendations. Evidence quality ranged from very low to moderate. Weak recommendations were issued for SAVI Dual, Cefaly, Relivion, and Nerivio in the treatment of acute migraine attacks, and for gammaCore Sapphire, Cefaly, and Nerivio in the preventive migraine treatment. Other cleared devices received no recommendations or have no eligible studies for the GRADE assessment. The primary limitations across studies included imprecision due to small sample sizes and various methodological concerns. Additionally, expert consensus recommendations were developed for devices and clinical scenarios not adequately covered by randomized controlled trials, including potential applications in pediatric populations, vestibular migraine, chronic migraine, menstrual migraine, and medication overuse headache. Conclusion Non-invasive neuromodulation devices offer promising alternatives to drug treatment for migraine management. These devices are safe and generally well tolerated and devoid of drug interactions. While current evidence quality varies, ongoing research and technological advancements show encouraging potential. Future studies should adhere to International Headache Society guidelines for neuromodulation device trials, address proper sham controls and blinding assessment, and account for patient adherence challenges in device use. Expanded insurance coverage would enhance cost-effectiveness and device accessibility. These guidelines provide a framework for clinical decision-making while highlighting areas requiring further research.
Prevalence of Cannabidiol (CBD) Use in an Outpatient Hand Surgery Clinic
Deckey, David G. , Ishimoto, A., Renfree, Sean P. , Noland, Shelley S. , Iturregui, Jose M. , Ishimoto, Alyssa, Renfree, Kevin J.

Mayo Clinic

Orthopedics | October 20, 2025 | Volume: 48 | Issue: 6 | Pages: 329-335

10.3928/01477447-20250904-01 | PMID 41114690 Get It

Background: The aim of this study was to evaluate the prevalence and perceived efficacy of cannabidiol (CBD) products in patients presenting to an orthopedic hand and upper extremity clinic. Materials and Methods: New patients seen for an initial surgical consultation between July and December 2022 were surveyed regarding CBD use, pain, and function. Pain was measured with the Numeric Pain Rating Scale (NPRS, 0–10) and function with the Single Assessment Numeric Evaluation (SANE, 0–100). Demographic and clinical factors were collected via chart review. Results: A total of 918 patients completed the survey (53% female; mean age 63 years, range 18–97). Joints involved included elbows (106), wrists (335), and hands/fingers (667). Common diagnoses included arthritis (199), tendinopathy (273), and nerve-related conditions (160). Overall, 15% (135/918) reported prior CBD use, and 39% (53/135) perceived pain relief. CBD users were more likely to be female (65% vs 51%; P =0.003), to present with wrist pathology (44% vs 35%; P =0.038), and to have arthritis (36% vs 19%; P <0.001). Compared to non-users, CBD users reported higher pain scores (mean NPRS 6.2 vs 5.1; P <0.001) and lower contralateral function (mean SANE 77.3 vs 87.4; P <0.001). Conclusions In this cohort, CBD use was uncommon, and only a minority of users reported subjective benefit. CBD users tended to report higher pain and worse function, particularly in the setting of wrist arthritis. CBD products did not appear to provide measurable objective improvement in pain or function. Further studies are needed to clarify optimal dosing, administration, and potential role in upper extremity care.
The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea
Mifsrud, Caroline S., Rushlow, David , Mifsud, Caroline S, Kolla, Bhanu Prakash , Mansukhani, Meghna P.

Mayo Clinic

Expert Opinion on Pharmacotherapy | October 20, 2025 | Volume: 26 | Issue: 14-15 | Pages: 1529-1538

10.1080/14656566.2025.2574848 | PMID 41114602 Get It

Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis
Ibrahim, Ramzi , Seby, Robert , Shaik, Abdullah, Tahsin, Malak , Abdelnabi, Mahmoud , Said, Nada, Bhakta, Mayurkumar D. , Sweeney, John P., Fortuin, David, Arsanjani, Reza, Ibrahim, Ramzi , Pham, Hoang Nhat , Farina, Juan M. , Yang, Eric H. , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Coronary Artery Disease | October 20, 2025 | Volume: 37 | Issue: 2 | Pages: 157-159

10.1097/mca.0000000000001576 | PMID 41114567 Get It

Conventional Versus High-Complexity Total Pelvic Exenteration for Locally Advanced and Locally Recurrent Rectal Cancer: An International Multicenter Study
Brown, Kilian G. M. , Sutton, Paul , Koh, Cherry , Aguiar, Samuel , Bezerra, Tiago S. , Clouston, H.W., Desouza, Ashwin , Dozois, Eric J. , Ersryd, Amanda L., Frizelle, Frank , Funder, Jonas Amstrup , Garfinkle, Richard , Glyn, Tamara , Kanemitsu, Yukihide , Palmer, Gabriella J., Pappou, Emmanouil P. , Quinn, Martha, Sahakitrungruang, Chucheep , Solbakken, Arne M. , Tiernan, Jim , Verhoef, Cornelis, Steffens, Daniel , Brown, Kilian G M , Garrett, Celine , Solomon, Michael J. , García‐Aguilar, Julio , Heriot, Alexander G. , Kong, Chia Yew , Kristensen, Helle Ø , Malakorn, Songphol , Mens, David M , Nilsson, Per Johan , Palmer, G. , Quyn, Aaron J. , Saklani, Avanish , Verhoef, Cornelis

Mayo Clinic

Diseases of the Colon & Rectum | October 20, 2025 | Volume: 69 | Issue: 1 | Pages: 34-41

10.1097/dcr.0000000000003986 | PMID 41114552 Get It

BACKGROUND: Pelvic exenteration is the treatment of choice for selected patients with locally advanced primary and recurrent rectal cancer. Involvement of major pelvic neurovascular structures and bone was historically considered a contraindication due to unacceptably high rates of morbidity and low R0 resection rates. OBJECTIVE: To compare the outcomes of these “high-complexity” exenterative resections to those of “conventional” pelvic exenteration. DESIGN: International multicenter retrospective cohort study. SETTINGS: Sixteen specialized exenteration centers. PATIENTS: Those who underwent total pelvic exenteration for locally advanced primary and recurrent rectal cancer between 2018 and 2023 at participating centers. MAIN OUTCOME MEASURES: Perioperative resource utilization, morbidity, mortality, and R0 resection rates were reported. RESULTS: Seven hundred sixty-three patients underwent total pelvic exenteration, of whom 478 (63%) and 285 (37%) required conventional and high-complexity procedures, respectively. High-complexity pelvic exenteration was associated with longer operating time (600 vs 480 minutes, p < 0.001 for locally advanced primary rectal cancer, 623 vs 480 minutes, p < 0.001 for locally recurrent rectal cancer), intensive care stay (2 vs 1 day, p < 0.001 and 3 vs 1 day, p < 0.001), hospital stay (19 vs 15 days, p = 0.008 and 23 vs 15 days, p < 0.001), and higher blood loss (2000 vs 1236 mL, p < 0.001 and 3000 vs 1600 mL, p < 0.001). Morbidity and mortality outcomes and R0 resection rates were similar between the groups. LIMITATIONS: Generalizability of findings outside of expert units. CONCLUSIONS: High-complexity pelvic exenteration for the treatment of rectal cancer is associated with similar morbidity, mortality, and R0 resection rates, but it has a significantly higher operative time, blood loss, and hospital resource utilization compared to conventional pelvic exenteration. In high-volume, specialized centers, these techniques are considered the standard of care for appropriately selected patients with tumors that involve major pelvic bone or neurovascular structures. See Video Abstract . EXENTERACIÓN PÉLVICA TOTAL CONVENCIONAL FRENTE A EXENTERACIÓN PÉLVICA TOTAL DE ALTA COMPLEJIDAD PARA EL CÁNCER RECTAL LOCALMENTE AVANZADO Y LOCALMENTE RECURRENTE: UN ESTUDIO MULTICÉNTRICO INTERNACIONAL ANTECEDENTES: La exenteración pélvica es el tratamiento de elección para determinados pacientes con cáncer rectal primario y recurrente localmente avanzado. La afectación de las principales estructuras neurovasculares y óseas pélvicas se consideraba históricamente una contraindicación debido a las tasas inaceptablemente altas de morbilidad y a las bajas tasas de resección R0. OBJETIVO: Comparar los resultados de estas resecciones exenteración «de alta complejidad» con los de la exenteración pélvica «convencional». DISEÑO: Estudio de cohorte retrospectivo multicéntrico internacional. ENTORNOS: Dieciséis centros especializados en exenteración. PACIENTES: Aquellos que se sometieron a una exenteración pélvica total por cáncer rectal primario y recurrente localmente avanzado entre 2018 y 2023 en los centros participantes. PRINCIPALES MEDIDAS DE RESULTADOS: Se informaron la utilización de recursos perioperatorios, la morbilidad, la mortalidad y las tasas de resección R0. RESULTADOS: 763 pacientes se sometieron a una exenteración pélvica total, de los cuales 478 (63 %) y 285 pacientes (37 %) requirieron procedimientos convencionales y de alta complejidad, respectivamente. La exenteración pélvica de alta complejidad se asoció con un tiempo quirúrgico más prolongado (600 frente a 480 minutos, p < 0,001 para el cáncer rectal primario localmente avanzado, 623 frente a 480 minutos, p < 0,001 para el cáncer rectal localmente recurrente), estancia en cuidados intensivos (2 frente a 1 día, p < 0,001 y 3 frente a 1 día, p < 0,001), estancia hospitalaria (19 frente a 15 días, p = 0,008 y 23 frente a 15 días, p < 0,001) y mayor pérdida de sangre (2000 frente a 1236 ml, p < 0,001 y 3000 frente a 1600 ml, p < 0,001). Los resultados de morbilidad y mortalidad, así como las tasas de resección R0, fueron similares entre los grupos. LIMITACIONES: Generalización de los resultados fuera de las unidades especializadas CONCLUSIONES: La exenteración pélvica de alta complejidad para el tratamiento del cáncer de recto se asocia con tasas similares de morbilidad, mortalidad y resección R0, pero con un tiempo quirúrgico, una pérdida de sangre y una utilización de recursos hospitalarios significativamente mayores en comparación con la exenteración pélvica convencional. En centros especializados con un gran volumen de casos, estas técnicas se consideran el tratamiento estándar para pacientes adecuadamente seleccionados con tumores que afectan a los huesos pélvicos principales o a las estructuras neurovasculares. ( AI-generated translation )
Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Ma
Kirtek, Timothy , Chen, Weina , Harris, Jaryse , Bagg, Adam , Foucar, Kathryn , Tam, Wayne , Orazi, Attilio , Hasserjian, Robert P. , Wang, Sa A. , Ng, David P. , Reichard, Kaaren K. , Symes, Emily , Zhang, Xinmin , Weinberg, Olga K. , Kirtek, Timothy J , Wang, Sa A , Ng, David P , Shi, Min , Zhang, Xinmin , Arber, Daniel A , Orazi, Attilio , Hsi, Eric D. , George, Tracy I. , Arber, Daniel A.

Mayo Clinic

American Journal of Hematology | October 18, 2025 | Volume: 101 | Issue: 1 | Pages: 70-78

10.1002/ajh.70116 | PMID 41108621 Get It

ABSTRACT The World Health Organization (WHO) 5th Edition and International Consensus Classification (ICC) have continued to delineate more genetically defined acute leukemias. Both recognize genetic aberrations associated with myelodysplastic syndromes/neoplasms (MDS) as defining MDS‐related AML (AML‐MR). Mutations in RUNX1 are included in this category in the ICC, but not WHO. The current classifications are unclear on how acute leukemias with ambiguous lineage (ALAL), including those of mixed lineage (MPAL) and those without a defined lineage (AUL), should be categorized in the presence of such mutations. Our multi‐institutional study aims to determine the significance of RUNX1 mutation in ALAL compared to de novo AML. Newly diagnosed MPAL, AUL, and AML with RUNX1 mutations were collected. ALAL with MDS‐related cytogenetics, BCR::ABL1 , KMT2A rearrangements, or ZNF384 or BCL11b abnormalities were excluded. We analyzed 17 cases of ALAL and 71 cases of AML that met inclusion criteria. ALAL‐ RUNX1 and AML‐ RUNX1 showed overlapping mutational landscapes with frequent comutations in MDS‐associated genes. No ALAL‐ RUNX1 or AML‐ RUNX1 cases showed concomitant TP53 mutation. ALAL‐ RUNX1 had more bone marrow blasts and more karyotypic abnormalities; however, neither impacted survival, nor did RUNX1 variant allele frequency (VAF). Survival analysis revealed similarly poor outcomes between them. AML‐directed therapies and allogeneic hematopoietic stem cell transplant trended toward improved survival in ALAL‐ RUNX1; however, it did not reach significance. Our results suggest ALAL‐ RUNX1 is associated with younger age, higher blasts, and more karyotypic abnormalities, but has similar clinical and genetic features and outcomes to AML‐ RUNX1 . Our findings suggest, like other MR mutations, RUNX1 ‐mutated ALALs should be included within AML‐MR.